Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Adaptive Phase I/II, Dose-Escalation, Multi-centric, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Immunogenicity of ZyCoV-D in Healthy Adult Volunteers

Next Previous
Trial Profile

An Adaptive Phase I/II, Dose-Escalation, Multi-centric, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Immunogenicity of ZyCoV-D in Healthy Adult Volunteers

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 Aug 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ZyCoV D (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions; Pharmacodynamics

    • Most Recent Events

    • 20 Aug 2021 According to a Zydus Cadila media release, results of the phase I part of this trial have published in the EClinical Medicine Journal of Lancet.
    • 03 Jan 2021 According to a Zydus Cadila media release, this trial has reviewed by an independent Data Safety Monitoring Board (DSMB) and reports were submitted to Central Drugs Standard Control Organisation (CDSCO) regularly for the update on safety outcome.
    • 24 Dec 2020 Status changed to completed, according to a Zydus Cadila media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top